Need immediate assistance? Call 1-518-730-0559 (Us-Canada Toll Free) or Contact Us

 

Cholesterol Lowering Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 – 2027

Table of Content

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Cholesterol Lowering Drugs Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Class Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Cholesterol Lowering Drugs Market Analysis and Forecasts, 2017–2027

5. Market Outlook

    5.1. Pipeline Analysis

    5.2. Key Drug Brand Analysis

    5.3. Key Merger & Acquisitions

    5.4. Pipeline Analysis 

    5.5. Global Prevalence of Cardiovascular Diseases

6. Global Cholesterol Lowering Drugs Market Analysis and Forecasts, by Drug Class 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug Class, 2017–2027

        6.3.1. Statins and Combination

        6.3.2. PCSK9 Inhibitors

        6.3.3. Bile Acid Sequestrants

        6.3.4. Fibrates

        6.3.5. Cholesterol Absorption Inhibitors

        6.3.6. Others

    6.4. Market Attractiveness, by Drug Class 

7. Global Cholesterol Lowering Drugs Market Analysis and Forecasts, by Indication 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Indication, 2017–2027

        7.3.1. Hypercholesterolemia

        7.3.2. Coronary Artery Disease

        7.3.3. Higher Triglycerides

    7.4. Market Attractiveness, by Indication 

8. Global Cholesterol Lowering Drugs Market Analysis and Forecasts, by Distribution Channel 

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017–2027

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Market Attractiveness, by Distribution Channel 

9. Global Cholesterol Lowering Drugs Market Analysis and Forecasts, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America 

        9.2.2. Europe 

        9.2.3. Asia Pacific 

        9.2.4. Latin America 

        9.2.5. Middle East & Africa 

    9.3. Market Attractiveness, by Region

10. North America Cholesterol Lowering Drugs Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Drug Class, 2017–2027

        10.2.1. Statins and Combination

        10.2.2. PCSK9 Inhibitors

        10.2.3. Bile Acid Sequestrants

        10.2.4. Fibrates

        10.2.5. Cholesterol Absorption Inhibitors

        10.2.6. Others

    10.3. Market Value Forecast, by Indication, 2017–2027

        10.3.1. Hypercholesterolemia

        10.3.2. Coronary Artery Disease

        10.3.3. Higher Triglycerides

    10.4. Market Value Forecast, by Distribution Channel, 2017–2027

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

    10.5. Market Value Forecast, by Country, 2017–2027

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis 

        10.6.1. By Drug Class 

        10.6.2. By Indication 

        10.6.3. By Distribution Channel 

        10.6.4. By Country

11. Europe Cholesterol Lowering Drugs Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Class, 2017–2027

        11.2.1. Statins and Combination

        11.2.2. PCSK9 Inhibitors

        11.2.3. Bile Acid Sequestrants

        11.2.4. Fibrates

        11.2.5. Cholesterol Absorption Inhibitors

        11.2.6. Others

    11.3. Market Value Forecast, by Indication, 2017–2027

        11.3.1. Hypercholesterolemia

        11.3.2. Coronary Artery Disease

        11.3.3. Higher Triglycerides

    11.4. Market Value Forecast, by Distribution Channel, 2017–2027

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2027

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis 

        11.6.1. By Drug Class 

        11.6.2. By Indication 

        11.6.3. By Distribution Channel 

        11.6.4. By Country/Sub-region

12. Asia Pacific Cholesterol Lowering Drugs Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Class, 2017–2027

        12.2.1. Statins and Combination

        12.2.2. PCSK9 Inhibitors

        12.2.3. Bile Acid Sequestrants

        12.2.4. Fibrates

        12.2.5. Cholesterol Absorption Inhibitors

        12.2.6. Others

    12.3. Market Value Forecast, by Indication, 2017–2027

        12.3.1. Hypercholesterolemia

        12.3.2. Coronary Artery Disease

        12.3.3. Higher Triglycerides

    12.4. Market Value Forecast, by Distribution Channel, 2017–2027

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2027

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis 

        12.6.1. By Drug Class 

        12.6.2. By Indication 

        12.6.3. By Distribution Channel 

        12.6.4. By Country/Sub-region

13. Latin America Cholesterol Lowering Drugs Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug Class, 2017–2027

        13.2.1. Statins and Combination

        13.2.2. PCSK9 Inhibitors

        13.2.3. Bile Acid Sequestrants

        13.2.4. Fibrates

        13.2.5. Cholesterol Absorption Inhibitors

        13.2.6. Others

    13.3. Market Value Forecast, by Indication, 2017–2027

        13.3.1. Hypercholesterolemia

        13.3.2. Coronary Artery Disease

        13.3.3. Higher Triglycerides

    13.4. Market Value Forecast, by Distribution Channel, 2017–2027

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2027

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis 

        13.6.1. By Drug Class 

        13.6.2. By Indication 

        13.6.3. By Distribution Channel 

        13.6.4. By Country/Sub-region

14. Middle East & Africa Cholesterol Lowering Drugs Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Drug Class, 2017–2027

        14.2.1. Statins and Combination

        14.2.2. PCSK9 Inhibitors

        14.2.3. Bile Acid Sequestrants

        14.2.4. Fibrates

        14.2.5. Cholesterol Absorption Inhibitors

        14.2.6. Others

    14.3. Market Value Forecast, by Indication, 2017–2027

        14.3.1. Hypercholesterolemia

        14.3.2. Coronary Artery Disease

        14.3.3. Higher Triglycerides

    14.4. Market Value Forecast, by Distribution Channel, 2017–2027

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Market Value Forecast, by Country/Sub-region, 2017–2027

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis 

        14.6.1. By Drug Class 

        14.6.2. By Indication 

        14.6.3. By Distribution Channel 

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player – Competition Matrix (By Tier and Size of companies)

    15.2. Market Share Analysis/Ranking, by Company (2018)

    15.3. Company Profiles

        15.3.1. Pfizer Inc.

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Company Financials

            15.3.1.3. Growth Strategies

            15.3.1.4. SWOT Analysis

        15.3.2. Sanofi

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Company Financials

            15.3.2.3. Growth Strategies

            15.3.2.4. SWOT Analysis

        15.3.3. GlaxoSmithKline plc

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Company Financials

            15.3.3.3. Growth Strategies

            15.3.3.4. SWOT Analysis

        15.3.4. Novartis AG

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Company Financials

            15.3.4.3. Growth Strategies

            15.3.4.4. SWOT Analysis

        15.3.5. Merck & Co., Inc. 

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Company Financials

            15.3.5.3. Growth Strategies

            15.3.5.4. SWOT Analysis

        15.3.6. Amgen, Inc.

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Company Financials

            15.3.6.3. Growth Strategies

            15.3.6.4. SWOT Analysis

        15.3.7. Takeda Pharmaceutical Company Limited

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Company Financials

            15.3.7.3. Growth Strategies

            15.3.7.4. SWOT Analysis

        15.3.8. Sun Pharmaceutical Industries Ltd.

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Company Financials

            15.3.8.3. Growth Strategies

            15.3.8.4. SWOT Analysis

        15.3.9. AbbVie, Inc. 

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Company Financials

            15.3.9.3. Growth Strategies

            15.3.9.4. SWOT Analysis

        15.3.10. Mylan N.V.

            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.10.2. Company Financials

            15.3.10.3. Growth Strategies

            15.3.10.4. SWOT Analysis

Custom Market Research Services

MRRSE offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Get A Free Custom Research Quote